chPD1-ICOS

chPD1-ICOS is an experimental chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of various solid tumors. The construct utilizes the extracellular domain of the programmed cell death protein 1 (PD-1) as its antigen-recognition component, allowing the T cells to target tumor cells expressing PD-1 ligands (PD-L1 and PD-L2). This chimeric PD1 (chPD1) receptor is fused to an ICOS (Inducible T-cell COStimulator) costimulatory domain and a CD3 zeta signaling domain. Preclinical research conducted at Longwood University evaluated this construct alongside other costimulatory variants (such as Dap10, CD28, and 4-1BB) across multiple murine cancer models, including melanoma, pancreatic, and breast cancers. While chPD1-ICOS demonstrated the ability to induce T-cell proliferation and tumor cell lysis, comparative studies indicated that the Dap10-containing variant (chPD1-Dap10) exhibited superior anti-tumor efficacy and a more favorable pro-inflammatory cytokine profile in vivo.

Other names

chimeric PD1-ICOS receptorchPD1-ICOS T cellschPD-1-ICOS T cellschPD 1-ICOS T cells